China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) is a China-based pharmaceutical company engaged in the research, development, manufacturing and marketing of small-molecule drugs primarily in the cardiovascular, anti-diabetic and anti-tumor therapeutic areas. Since its founding, the company has focused on producing high-quality generic and branded pharmaceuticals, with a growing pipeline of novel drug candidates. Headquartered in Fujian Province, China SXT Pharmaceuticals operates state-of-the-art manufacturing and research facilities that comply with international quality standards.
The company’s core product portfolio includes a range of cardiovascular agents such as anti-hypertensives and cholesterol-lowering medications, as well as formulations for diabetes management and oncology supportive care. Through a combination of in-house development and strategic partnerships, China SXT Pharmaceuticals has secured regulatory approvals for its products in domestic and select overseas markets. Its active pharmaceutical ingredients (APIs) and finished dosage forms are distributed to hospitals, pharmacies and distributors across China and exported to regions in Southeast Asia and the Middle East.
Over the years, China SXT Pharmaceuticals has invested significantly in its R&D capabilities, establishing dedicated laboratories for preclinical studies and clinical trials. The company’s research efforts are aimed at optimizing existing therapies and advancing innovative molecules, including proprietary cardiovascular compounds and next-generation diabetes treatments. By maintaining a robust intellectual property portfolio, China SXT Pharmaceuticals seeks to enhance patient access to cost-effective medications while supporting long-term growth through the introduction of new therapeutic options.
Led by Chief Executive Officer Peng Hong and Chief Scientific Officer Dr. Liu Wei, the management team combines extensive industry experience with a commitment to regulatory compliance and quality assurance. The board of directors includes seasoned professionals who oversee corporate governance and strategic planning. As China SXT Pharmaceuticals continues to expand its commercial footprint, it remains focused on building sustainable partnerships, enhancing manufacturing efficiencies and delivering value to healthcare providers and patients worldwide.
AI Generated. May Contain Errors.
Free SXTC Stock Alerts